Debananda Das

Debananda Das

UNVERIFIED PROFILE

Are you Debananda Das?   Register this Author

Register author
Debananda Das

Debananda Das

Publications by authors named "Debananda Das"

Are you Debananda Das?   Register this Author

36Publications

537Reads

38Profile Views

Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.

Curr Top Med Chem 2019 ;19(18):1621-1649

Department of Molecular Virology, Tokyo Medical and Dental University (TMDU), Tokyo 113-8519, Japan.

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/173455/article
Publisher Site
http://dx.doi.org/10.2174/1568026619666190712204603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132033PMC
November 2019

Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.

Sci Rep 2019 03 18;9(1):4828. Epub 2019 Mar 18.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892-1868, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-019-41080-w
Publisher Site
http://dx.doi.org/10.1038/s41598-019-41080-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423129PMC
March 2019

The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

Cell Chem Biol 2018 10 30;25(10):1268-1278.e3. Epub 2018 Aug 30.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1868, USA; Department of Refractory Viral Infection, National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama Shinjuku, Tokyo 162-8655, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2018.07.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261781PMC
October 2018

GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.

Antimicrob Agents Chemother 2018 05 26;62(5). Epub 2018 Apr 26.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.02060-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923169PMC
May 2018

Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.

mBio 2018 03 6;9(2). Epub 2018 Mar 6.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/mBio.02425-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844992PMC
March 2018

C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.

J Virol 2015 Nov 18;90(5):2180-94. Epub 2015 Nov 18.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Departments of Infectious Diseases and Hematology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan Research Institute and Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JVI.01829-15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810716PMC
November 2015

A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.

Antimicrob Agents Chemother 2015 May 17;59(5):2625-35. Epub 2015 Feb 17.

Departments of Infectious Diseases and Hematology, Kumamoto University School of Medicine, Kumamoto, Japan Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.04757-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394833PMC
May 2015

Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.

Antimicrob Agents Chemother 2015 Apr 12;59(4):1895-904. Epub 2015 Jan 12.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Departments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Kumamoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.04654-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356787PMC
April 2015

Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Proc Natl Acad Sci U S A 2014 Aug 4;111(33):12234-9. Epub 2014 Aug 4.

Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Graduate School of Medicine, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan;Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1400027111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142999PMC
August 2014

A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.

Antimicrob Agents Chemother 2014 Jul 21;58(7):3679-88. Epub 2014 Apr 21.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA Departments of Hematology and Infectious Diseases, Kumamoto University Graduate School of Biomedical Sciences, Kumamoto, Japan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.00107-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068604PMC
July 2014

CCR5 inhibitors: emergence, success, and challenges.

Expert Opin Emerg Drugs 2012 Jun 25;17(2):135-45. Epub 2012 Apr 25.

National Cancer Institute, Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, Bethesda 20892, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2012.673584DOI Listing
June 2012

Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.

J Chem Inf Model 2009 Dec;49(12):2851-62

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ci900320pDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860540PMC
December 2009

Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.

Adv Pharmacol 2008 ;56:169-97

The Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1054-3589(07)56006-0DOI Listing
January 2008

Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

J Biol Chem 2007 Sep 17;282(39):28709-20. Epub 2007 Jul 17.

Department of Hematology, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, 1-1-1 Honjo, Kumamoto 860-8556, Japan.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M703938200
Publisher Site
http://dx.doi.org/10.1074/jbc.M703938200DOI Listing
September 2007

A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

Antimicrob Agents Chemother 2007 Jun 19;51(6):2143-55. Epub 2007 Mar 19.

Departments of Infectious Diseases and Hematology, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.01413-06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891396PMC
June 2007

Structural and molecular interactions of CCR5 inhibitors with CCR5.

J Biol Chem 2006 May 13;281(18):12688-98. Epub 2006 Feb 13.

Department of Hematology, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Kumamoto 860-8556, Japan.

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.M512688200
Publisher Site
http://dx.doi.org/10.1074/jbc.M512688200DOI Listing
May 2006

Altered HIV-1 Gag protein interactions with cyclophilin A (CypA) on the acquisition of H219Q and H219P substitutions in the CypA binding loop.

J Biol Chem 2006 Jan 7;281(2):1241-50. Epub 2005 Nov 7.

Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, NCI, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M505920200DOI Listing
January 2006